

Beovu (brolucizumab-dblI)

| Override(s) | Approval Duration |
|---------------------|-------------------|
| Prior Authorization | 1 year |

| Medications | Dosing Limit |
|--|--|
| Beovu (brolucizumab-dblI) 6 mg vial & pre-filled syringe | 6 mg per eye; each eye may be treated as frequently as every 8 weeks** |

**May approve the following for initiation of therapy:

- I. Age-related macular degeneration: One 6 mg dose per eye monthly for the first three (3) doses; **OR**
- II. Diabetic macular edema (DME): One 6 mg dose per eye every six weeks for the first five (5) doses.

APPROVAL CRITERIA

Requests for Beovu (brolucizumab-dblI) may be approved if the following criteria are met:

- I. Individual has one of the following:
 - A. Individual has a diagnosis of established neovascular “wet” age-related macular degeneration: **OR**
 - B. Individual has a diagnosis of diabetic macular edema (DME) (including DME with diabetic retinopathy of any severity).

Requests for intravitreal injections of Beovu (brolucizumab-dblI) may not be approved when the above criteria are not met and for all other indications.

Key References:

1. American Academy of Ophthalmology. Preferred Practice Pattern Guidelines: Retinal Vein Occlusions. October 2019. Available at: <https://www.aao.org/preferred-practice-pattern/retinal-vein-occlusions-ppp>. Accessed October 15, 2021.
2. American Academy of Ophthalmology. Preferred Practice Pattern Guidelines: Age-Related Macular Degeneration. October 2019. Available at: <https://www.aao.org/preferred-practice-pattern/age-related-macular-degeneration-ppp>. Accessed October 15, 2021.
3. American Academy of Ophthalmology. Preferred Practice Pattern Guidelines: Diabetic Retinopathy. October 2019. Available at: <https://www.aao.org/preferred-practice-pattern/diabetic-retinopathy-ppp>. Accessed October 15, 2021.
4. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2021. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
5. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: October 9, 2021.
6. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
7. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2021; Updated periodically.
8. Sankar MJ, Sankar J, Chandra P. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst Rev 2018; 1:CD009734.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.